We haven't quite wrapped up the season of trend reports on biotech deals for the second quarter, as PricewaterhouseCoopers today has provided another mixed bag results for dealmaking in the life sciences sector. After some heavy deal flow in the first three months of 2013, the second quarter showed a 40% slide in deal volume compared with the previous one. The good news is that deal value increased 66% in the second quarter compared with the first quarter. Study (PDF)